BURNABY, BC, June 19 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX- V: WBI), a biotechnology company developing therapeutic drugs for the
treatment of anti-inflammatory and auto-immune diseases and cancer, is pleased
to announce that the clinical component of a Phase IIa trial on Atopic
Dermatitis (a form of eczema) has been completed. The final report on this
randomized, double-blinded, vehicle-controlled study to evaluate the safety,
tolerability and efficacy of topically applied WBI-1001 cream in subjects with
Atopic Dermatitis (AD) is expected later this summer.
